Head and Neck Cancer Drugs Market - Increase In Use Of Combination Therapy And Growth In Demand For Target Immune Therapy Are Expected To Boost The Market Growth In The Coming Years

Recent launch of novel drugs for treatment of head and neck cancer, rise in geriatric population across the world, and surge in consumption of tobacco & alcohol has fueled the growth of global head & neck cancer drugs market.

Allied Market Research recently published a report, titled, “Head and Neck Cancer Drugs Market by Drug Class (Chemotherapy, Immunotherapy, and Targeted Therapy) and Sales Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Stores): Global Opportunity Analysis and Industry Forecast, 2018–2025”. According to the report, the global head & neck cancer drugs market accounted for $1.30 billion in 2017 and is projected to $2.28 billion by 2025, registering a CAGR of 7.3% during the period from 2018 to 2025.

Download PDF Report Sample with statistical info @ https://www.alliedmarketresearch.com/request-sample/5174

Segmentation Analysis of the Industry
The market is divided on the basis of drug class, sales channel, and geography. Based on drug class, the market is segmented into chemotherapy, immunotherapy, and targeted therapy. The chemotherapy segment held the largest share in 2017, contributing nearly half of the total market share. However, the immunotherapy segment is expected to manifest the fastest CAGR of 12.1% during the forecast period.

On the basis of sales channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online stores. The drug stores & retail pharmacies segment dominated the market in terms of revenue, contributing about 58% of the total market share in 2017. However, the online stores segment is projected to portray the fastest CAGR of 10.2% through 2025.

Based on geography, the market is segmented into North America, Europe, Asia-Pacific, and Latin America, Middle East and Africa (LAMEA). North America region held the largest share in 2017, accounting about half of the total market. However, Asia-Pacific region is estimated to manifest the fastest CAGR of 9.7% during the forecast period.
Industry Key Players

The report includes the major market players in the industry, such as AstraZeneca PLC, Eli Lilly and Company (ARMO Biosciences), F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Merck & Co., Inc., Novartis AG, Bristol-Myers Squibb Company, Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.), Immutep Limited, Merck KGaA (EMD Serono, Inc.), and Pfizer Inc.

Purchase This Report with Discounted Price @ https://www.alliedmarketresearch.com/checkout-final/f95b22bb1917e9967a3a67c35a62112f

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975

help@alliedmarketresearch.com

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.